Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  JAMA psychiatry

• Publication date

  2015-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/jamapsychiatry.2014.3043PMID 25760692
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• "Every 'never' I ever said came true": transitions from opioid pills to heroin injecting.

  2014cited by this paper
• Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation.

  2014cited by this paper
• Development and impact of prescription opioid abuse deterrent formulation technologies.

  2014cited by this paper
• Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation†

  2014cited by this paper
• The changing face of heroin use in the United States: a retrospective analysis of the past 50 years.

  2014cited by this paper
• The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers.

  2014cited by this paper
• Update on tamper-resistant drug formulations.

  2013cited by this paper
• Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics

  2013cited by this paper
• Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers - United States, 2002-2004 and 2008-2010.

  2013cited by this paper
• Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment.

  2013cited by this paper
• Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010.

  2013cited by this paper
• Effect of abuse-deterrent formulation of OxyContin.

  2012cited by this paper
• Initiation into prescription opioid misuse amongst young injection drug users.

  2012cited by this paper
• A review of abuse-deterrent opioids for chronic nonmalignant pain.

  2012cited by this paper
• Prescription Opioid Use Among Patients Seeking Treatment for Opioid Dependence

  2010cited by this paper
• Impact of South American heroin on the US heroin market 1993-2004.

  2009cited by this paper
• Internet-based Survey of Nonmedical Prescription Opioid Use in the United States

  2008cited by this paper
• Prescription OxyContin abuse among patients entering addiction treatment.

  2007cited by this paper
• A Profile of OxyContin Addiction

  2004cited by this paper
• Oxycodone involvement in drug abuse deaths: a DAWN-based classification scheme applied to an oxycodone postmortem database containing over 1000 cases.

  2003cited by this paper

• Systematic review of real-world data associated with opioid scheduling and nonmedical use.

  2026cites this paper
• Purdue’s development of abuse-deterrent formulation opioids as a response to market competition: An industry documents analysis

  2026cites this paper
• Abuse-deterrent wearable device with potential for extended delivery of opioid drugs

  2025cites this paper
• Racial Differences in Pain Medication Prescribed for Injury during Emergency Department Visits.

  2025cites this paper
• Use of Causal Framework to Evaluate Effect of Abuse Deterrent Properties of Extended‐Release Oxycodone on Tampering in a Real‐World Settings

  2025cites this paper
• Spillover Effects of Opioid Abuse on Skilled Human Capital and Innovation Activity

  2025cites this paper
• Atp1a2 and Kcnj9 Are Candidate Genes Underlying Sensitivity to Oxycodone‐Induced Locomotor Activation and Withdrawal‐Induced Anxiety‐Like Behaviors in C57BL/6 Substrains

  2025cites this paper
• Postmarketing Research for Opioid Abuse-Deterrent Formulations: A Narrative Review

  2025cites this paper
• Reframing the Overdose Crisis: Stigma, Industry Influence, and the Politics of Abuse-Deterrent Opioids

  2025cites this paper
• A Conceptual Model of Opioid Use Pathways: Addressing the Prescription-to-Illegal Opioid “Transition”

  2025cites this paper
• The Baltic and Nordic responses to the first Taliban poppy ban: Implications for Europe & synthetic opioids today.

  2024cites this paper
• The Opioid Crisis and the Location of Work: Evidence from Online Job Profile Data

  2024cites this paper
• Predicting first use of heroin from prescription opioid use subtypes: Insights from the Monitoring the Future longitudinal panel.

  2024cites this paper
• Comparing the effects of decreasing prescription opioid shipments and the release of an abuse deterrent OxyContin formulation on opioid overdose fatalities in WV: an interrupted time series study

  2024cites this paper
• Spillovers of the Heroin Epidemic on Grandparent Caregiving

  2024cites this paper
• Hiding Behind Complexity: Supply Chain, Oversight, Race, and the Opioid Crisis

  2024cites this paper
• Nasal absorption of oxycodone predicted using a novel computational fluid dynamics-physiologically based pharmacokinetic model.

  2024cites this paper
• Review of Opioid Abuse-Deterrent Formulations: Impact and Barriers to Access

  2024cites this paper
• Oxymorphone and Oxycodone Pharmacy Purchases in US Counties: Prelude to the Largest Rural Human Immunodeficiency Virus Outbreak in US History

  2024cites this paper
• The Growth of Illicit Drug Use and Its Effects on Murder Rates

  2024cites this paper
• Atp1a2 and Kcnj9 are candidate genes underlying sensitivity to oxycodone-induced locomotor activation and withdrawal-induced anxiety-like behaviors in C57BL/6 substrains

  2024cites this paper
• Abuse-deterrent formulations and opioid-related harms in North Carolina, 2010-2018

  2024cites this paper
• Understanding the rise in overdose deaths involving opioids and non-opioid prescription drugs in the United States.

  2023cites this paper
• Revisiting the Oxycontin Reformulation: The Role of Licit Substitutes

  2023cites this paper
• A Chewing Study of Abuse-Deterrent Tablets Containing Polyethylene Oxide Using a Robotic Simulator

  2023cites this paper
• Feasibility and acceptability of online opioid overdose education and naloxone distribution: Study protocol and preliminary results from a randomized pilot clinical trial.

  2023cites this paper
• Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System

  2023cites this paper
• The Effect of Naloxone Access Laws on Fatal Synthetic Opioid Overdose Fatality Rates

  2023cites this paper
• Opioid epidemic: lessons learned and updated recommendations for misuse involving prescription versus non-prescription opioids

  2022cites this paper
• The effects of opioid policy changes on transitions from prescription opioids to heroin, fentanyl and injection drug use: a qualitative analysis

  2022cites this paper
• Shifts in substance use patterns among a cohort of people who use opioids after delisting of OxyContin in BC, Canada: An interrupted time series study.

  2022cites this paper
• Must‐access prescription drug monitoring programs and retail opioid sales

  2022cites this paper
• A US Retrospective Claims Analysis Comparing Healthcare Costs of Patients Transitioning from Immediate-Release Oxycodone to Two Different Formulations of Extended-Release Oxycodone: Xtampza ER or OxyContin

  2022cites this paper
• Kentucky pharmacists' experiences in dispensing abuse-deterrent opioid analgesics.

  2022cites this paper
• Prescription Opioid Resiliency and Vulnerability: A Mixed-Methods Comparative Case Study

  2022cites this paper
• Pharmacovigilance Signals of the Opioid Epidemic over 10 Years: Data Mining Methods in the Analysis of Pharmacovigilance Datasets Collecting Adverse Drug Reactions (ADRs) Reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS)

  2022cites this paper
• Choices and Implications when Measuring the Local Supply of Prescription Opioids

  2022cites this paper
• Opioid Epidemic and Mortgage Default

  2022cites this paper
• Estimates of Probabilities of Successful Development of Pain Medications: An Analysis of Pharmaceutical Clinical Development Programs from 2000 to 2020

  2022cites this paper
• The Hazards of Unwinding the Prescription Opioid Epidemic: Implications for Child Maltreatment

  2022cites this paper
• An Evaluation of the Effect of the OxyContin Reformulation on Unintentional Fatal and Nonfatal Overdose

  2022cites this paper
• The OxyContin Reformulation Revisited: New Evidence From Improved Definitions of Markets and Substitutes

  2021influential citation
• Behavioral Responses to Supply-Side Drug Policy During the Opioid Epidemic

  2021cites this paper
• A limited access oral oxycodone paradigm produces physical dependence and mesocorticolimbic region-dependent increases in DeltaFosB expression without preference.

  2021cites this paper
• The release of abuse-deterrent OxyContin and adolescent heroin use.

  2021cites this paper
• A prescribing protocol decreases the rate of chronic opioid use in orthopaedic trauma patients: a prospective quality improvement study

  2021cites this paper
• Labor Market Effects of the Oxycodone-Heroin Epidemic

  2021influential citation
• Effectiveness of Policies for Addressing the US Opioid Epidemic: A Model-Based Analysis from the Stanford-Lancet Commission on the North American Opioid Crisis

  2021cites this paper
• Prescription opioid policies and associations with opioid overdose and related adverse effects.

  2021cites this paper
• Abuse Deterrent Formulations in Constraining the Abuse Potential of Prescription Medicines: A Myth or Truth.

  2021cites this paper
• The opioid crisis and HIV in the USA: deadly synergies.

  2021cites this paper
• Racial/ethnic differences in prescription opioid misuse and heroin use among a national sample, 1999-2018.

  2021cites this paper
• When Innovation Goes Wrong: Technological Regress and the Opioid Epidemic

  2021cites this paper
• Opioid misuse and family structure: Changes and continuities in the role of marriage and children over two decades.

  2021cites this paper
• Health(care) in the Crisis: Reflections in Science and Society on Opioid Addiction

  2021cites this paper
• Methodological challenges and proposed solutions for evaluating opioid policy effectiveness

  2020cites this paper
• Can Administrative Capacity Address Wicked Problems? Evidence From the Frontlines of the American Opioid Crisis

  2020cites this paper
• Is the Rise in Illicit Opioids Affecting Labor Supply and Disability Claiming Rates?

  2020cites this paper
• Exploring the impact of the opioid epidemic in Black and Hispanic communities in the United States

  2020cites this paper
• Regulating Opioid Supply Through Insurance Coverage.

  2020cites this paper
• Prescription Opioid Dispensing Patterns Prior to Heroin Overdose in a State Medicaid Program: a Case-Control Study

  2020cites this paper
• Pills, Powders, and Overdose: An Analysis of America's Illicit Fentanyl Crisis

  2020cites this paper
• Oxycodone in the Opioid Epidemic: High ‘Liking’, ‘Wanting’, and Abuse Liability

  2020cites this paper
• Reformulation of oxycodone 80 mg to prevent misuse: A cohort study assessing the impact of a supply-side intervention.

  2020cites this paper
• Abuse-Deterrent Opioid Formulations and the Opioid Crisis: A Pharmacist's Perspective.

  2020cites this paper
• Dilemma of Addiction and Respiratory Depression in the Treatment of Pain: A Prototypical Endomorphin as a New Approach.

  2020cites this paper
• Opioid analgesics and narcotic antagonists

  2020cites this paper
• The Potential Role of Dual Mechanistic Opioids in Combating Opioid Misuse

  2020cites this paper
• Patterns of Prescription Opioid Use Prior to Self-reported Heroin Initiation.

  2020cites this paper
• Injection Opioid and Injection Methamphetamine Use in the Rural United States: A Systematic Review and Network Analysis

  2020cites this paper
• Latent classes of lifetime drug use disorder in national epidemiological survey on alcohol and related conditions - III.

  2020cites this paper
• Effect of physical manipulation on the oral pharmacokinetic profile of Xtampza® ER (oxycodone DETERx® formulation): A review of published studies.

  2020cites this paper
• Replacement of current opioid drugs focusing on MOR-related strategies.

  2020cites this paper
• Variability in opioid prescribing following fracture fixation: A retrospective cohort analysis

  2020cites this paper
• The Evolving Consequences of OxyContin Reformulation on Drug Overdoses

  2020cites this paper
• The state of the science in opioid policy research.

  2020cites this paper
• Achieving Opioid-Free Major Colorectal Surgery: Is It Possible?

  2020cites this paper
• Linking prescription opioids and infectious diseases.

  2020cites this paper
• Impact of the Young Adult Dependent Coverage Expansion on Opioid Overdoses and Deaths: a Quasi-Experimental Study

  2020cites this paper
• Drug Policy: The Effect of Medical Marijuana on Opioid Consumption During the US Opioid Epidemic

  2020cites this paper
• Pharmacokinetic and pharmacodynamic considerations in developing a response to the opioid epidemic

  2020cites this paper
• Must-access prescription drug monitoring programs and the opioid overdose epidemic: The unintended consequences.

  2020cites this paper
• Pushing the (Visual) Narrative: The Effects of Prior Knowledge Elicitation in Provocative Topics

  2020cites this paper
• Chroniques d’une toxicomanie annoncée

  2020cites this paper
• Prescription Drug Monitoring Program Mandates: Impact On Opioid Prescribing And Related Hospital Use.

  2019cites this paper
• Structure-Activity Relationship Studies of Synthetic Cathinones and Related Agents

  2019influential citation
• Long-term Safety and Tolerability of NKTR-181 in Patients with Moderate to Severe Chronic Low Back Pain or Chronic Noncancer Pain: A Phase 3 Multicenter, Open-Label, 52-Week Study (SUMMIT-08 LTS)

  2019cites this paper
• Mining social media for prescription medication abuse monitoring: a review and proposal for a data-centric framework

  2019cites this paper
• Behavioral economic demand metrics for abuse deterrent and abuse potential quantification.

  2019cites this paper
• Evaluation of Abuse-Deterrent Characteristics of Tablets Prepared via Hot-Melt Extrusion

  2019cites this paper
• A Biopsychosocial Overview of the Opioid Crisis: Considering Nutrition and Gastrointestinal Health

  2019cites this paper
• Opioid use and misuse: health impact, prevalence, correlates and interventions

  2019cites this paper
• Economic decline, incarceration, and mortality from drug use disorders in the USA between 1983 and 2014: an observational analysis.

  2019cites this paper
• Causal inference for evaluating prescription opioid abuse using trend‐in‐trend design

  2019cites this paper
• Mitigation of IV Abuse Through the Use of Abuse‐Deterrent Opioid Formulations: An Overview of Current Technologies

  2019cites this paper
• A recent history of opioid use in the US: Three decades of change

  2019influential citation
• How Should the United States Respond to the Opioid Addiction and Overdose Epidemic?

  2019cites this paper
• How the Reformulation of OxyContin Ignited the Heroin Epidemic

  2019cites this paper
• Real-world misuse, abuse, and dependence of abuse-deterrent versus non-abuse-deterrent extended-release morphine in Medicaid non-cancer patients

  2019cites this paper
• ORIGINS OF THE OPIOID CRISIS AND ITS ENDURING IMPACTS.

  2019cites this paper